Literature DB >> 17896901

Acute interstitial nephritis associated with coadministration of vancomycin and ceftriaxone: case series and review of the literature.

Roda Plakogiannis1, Anna Nogid.   

Abstract

We report what we believe to be the first two cases of acute interstitial nephritis associated with vancomycin and ceftriaxone therapy in adults. A 40-year-old man with a medical history of traumatic brain injury and tonic-clonic seizure disorder was admitted to the hospital with a seizure episode and temperature of 103 degrees F. He was administered ceftriaxone, vancomycin, and acyclovir for suspected bacterial and/or viral meningitis. On day 4, the patient was noted to have diffuse erythematous plaques on the neck, chest, arms, abdomen, and back, as well as an elevated serum creatinine level of 3.1 mg/dl (baseline 0.9 mg/dl) and an elevated eosinophil count (6%). Dermatology and renal consultations were obtained, and a diagnosis of suspected acute interstitial nephritis was made. After a 3-day course of antibiotic treatment (day 4 of hospitalization), all antibiotics were discontinued and topical triamcinolone 0.1% ointment and hydrocortisone 2.5% cream were begun for the rash. The patient was discharged 5 days later with improvement in the rash, serum creatinine level (1.0 mg/dl), and eosinophil count (0.9%). A 59-year-old woman with a medical history of diabetes mellitus was admitted to the hospital with a serum creatinine level of 3.7 mg/dl, eosinophil count of 8.4%, and fractional excretion of sodium of 2.94%. The patient had been receiving treatment with vancomycin and ceftriaxone for osteomyelitis for 28 days before this hospital admission. Her baseline serum creatinine level (before antibiotic therapy) was 1.0 mg/dl. Renal consultation was obtained, and a diagnosis of probable acute interstitial nephritis was made. Ceftriaxone and vancomycin were discontinued, and her serum creatinine level gradually decreased to 3.3 mg/dl and then further to 1.5 mg/dl over the next 3 months. Use of the Naranjo adverse drug reaction probability scale revealed that the adverse reaction was possible in the first case and probable in the second case. Health care professionals need to be cognizant that drug-induced acute interstitial nephritis can be associated with concomitant administration of ceftriaxone and vancomycin therapy. Early detection of this rare adverse reaction is paramount in order to prevent acute renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896901     DOI: 10.1592/phco.27.10.1456

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.

Authors:  Reza Zonozi; Aozhou Wu; Jung-Im Shin; Alex Secora; Josef Coresh; Lesley A Inker; Alex R Chang; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2019-01       Impact factor: 7.616

2.  Case Report: Vancomycin-Associated Tubulointerstitial Nephritis in Clinical Practice-Case Report and Review of Literature.

Authors:  Lakshmi Kannan; Rishi Raj
Journal:  Front Med (Lausanne)       Date:  2022-05-31

Review 3.  Review of vancomycin-induced renal toxicity: an update.

Authors:  Oluwatoyin Bamgbola
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-30       Impact factor: 3.565

Review 4.  Kidney biopsy findings in vancomycin-induced acute kidney injury: a pooled analysis.

Authors:  Ioannis Bellos; Vasilios Pergialiotis; Despina N Perrea
Journal:  Int Urol Nephrol       Date:  2021-03-14       Impact factor: 2.370

Review 5.  Glycopeptide Hypersensitivity and Adverse Reactions.

Authors:  Vanthida Huang; Nicola A Clayton; Kimberly H Welker
Journal:  Pharmacy (Basel)       Date:  2020-04-21

Review 6.  Acute kidney injury induced by antimicrobial agents in the elderly: awareness and mitigation strategies.

Authors:  Fumihiro Mizokami; Tomohiro Mizuno
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 4.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.